Developer docs
API playgroundTry for free, no card

Search company profiles

Clexio Biosciences

Full company profile

uuid000a9pn

Namestring
Clexio Biosciences
Legal namestring
Clexio Biosciences Ltd.
Websiteurl
clexio.com
Company typeenum
Private
Founded yearint
2009
Descriptiontext

Clexio Biosciences Ltd. is a clinical-stage pharmaceutical company founded in Israel (Yokne'am headquarters with a secondary office in Petach Tikva) that designs novel small-molecule drugs based on validated mechanisms of action in neuropsychiatry. Its pipeline targets two indications with documented unmet need: Major Depressive Disorder (MDD) and Epilepsy. The lead asset, CLE-100, is an oral NMDA receptor antagonist tablet (esketamine-class mechanism) with high affinity to the PCP site of the NMDA receptor, being developed as an add-on treatment for MDD patients with inadequate response to standard antidepressants; it is currently in Phase 2 multicenter studies in the United States (SOLEO study, initiated April 2024, 50% enrolled by December 2024), following the earlier CLEO Phase 2 proof-of-concept study in 2023. The second asset, CLE-043, is a KV7.2/3 channel opener in preclinical development for Epilepsy and MDD, with a lead compound identified. CLE-100 is protected by three issued US method-of-use patents and three additional allowed US patents, and the program has been supported by patient-advocacy engagement (DBSA) and translational neuroscience partnerships (NeuroKaire).

The company is privately held, pre-revenue, and operates with an 11-50 person organization. Its commercial model will ultimately rely on pharmaceutical drug sales following regulatory approval, with the addressable patient population being adults with treatment-resistant MDD — a segment in which approximately one-third of patients do not achieve remission even after four antidepressant trials, according to the STAR*D data Clexio cites. The team is composed largely of former Teva Pharmaceuticals executives across R&D, clinical, regulatory, legal, and business development functions, complemented by senior leaders with FDA, Roche-Genentech, Merck, and Novo Nordisk backgrounds. The go-to-market is currently clinical-trial-driven: US-based Phase 2 site activation, ClinicalTrials.gov recruitment (NCT06340958), patient advocacy partnerships, and scientific conference presentations (ASCP 2023, CNS Summit 2024, Oxford Conference on Ketamine and Related Compounds). Clexio discloses no commercial customers, no licensing revenue, and no external funding rounds in the available data, making its economics entirely dependent on continued clinical progress and future capital formation.

Short descriptiontext

Clexio Biosciences is a clinical-stage Israeli pharmaceutical company developing CLE-100 (an oral NMDA receptor antagonist in Phase 2 trials) and CLE-043 (a KV7.2/3 channel opener in preclinical) for patients with treatment-resistant Major Depressive Disorder and Epilepsy.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersJerusalem, Israel
HQ citystring
Jerusalem
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage pharmaceuticals, NMDA receptor antagonists, neuropsychiatric drug development, Major Depressive Disorder treatment, epilepsy therapeutics
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-Stage Neuropsychiatric Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Drug Sales
TypeOne Time License
Description

Pre-revenue clinical-stage pharmaceutical company. Revenue will be generated through commercialization of novel drugs following FDA and regulatory approval. The company is developing CLE-100 for Major Depressive Disorder and CLE-043 for Epilepsy and MDD.

clexio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Clexio Biosciences is a clinical-stage pharmaceutical company designing novel drug candidates based on validated Mechanisms of Action in Neuropsychiatry. Its lead asset CLE-100 is an NMDA receptor antagonist tablet in Phase 2 trials as an add-on therapy for patients with Major Depressive Disorder who have inadequate response to standard antidepressants. Its second asset CLE-043 is a KV7.2/3 channel opener in preclinical development for Epilepsy and MDD.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Phase 2 CLEO study showed good safety profile and promising efficacy in subgroup of subjects enrolled during post-acute Covid period
+1 more record
Product overview1 text field

Clexio is a multi-asset clinical-stage pharmaceutical company developing two novel drug candidates based on validated Mechanisms of Action in Neuropsychiatry. The lead product, CLE-100 (an NMDA antagonist tablet), is currently in Phase 2 multicenter studies in the United States for Major Depressive Disorder. The second candidate, CLE-043 (a KV7.2/3 channel opener), is in preclinical development for Epilepsy and MDD. Both products target unmet needs in patients who have not found effective solutions for their neuropsychiatric conditions.

Product and service2 records
1CLE-100
CategoryDrug candidate (CNS / neuropsychiatry)
Description

CLE-100 is an investigational NMDA receptor antagonist tablet developed as an add-on treatment for patients with Major Depressive Disorder who have inadequate response to standard antidepressant therapy, targeting a more rapid antidepressant effect than most current medications.

2CLE-043
CategoryDrug candidate (CNS / epilepsy)
Description

CLE-043 is a KV7.2/3 channel opener being developed for the treatment of Epilepsy and Major Depressive Disorder; currently in preclinical development with lead compound identified.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-11-01
Description

Collaboration on profiling drug response mechanisms and patient sub-populations through readouts from a biobank of patient-derived neurons. Collaboration presented at CNS Summit 2024.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Clexio partnered with the Depression Bipolar Support Alliance (DBSA) to evaluate the readability of the Informed Consent Form (ICF) designed for their Phase 2 trial in patients with Major Depressive Disorder. The feedback from patients enabled modifications to better explain trial procedures and ensure clear, concise information.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Markets Spravato (esketamine), an FDA-approved NMDA antagonist for treatment-resistant depression. Represents the dominant incumbent CLE-100 must differentiate against.

TypeEmerging player
Description

Developing psilocybin-based therapy for treatment-resistant depression. Competes for the same TRD patient population with a novel mechanism rather than NMDA antagonism.

TypeDirect peer
Description

Clinical-stage neuroscience company developing precision therapeutics for brain diseases including depression. Comparable in stage, indication focus, and pipeline breadth.

4atai Life Sciences
TypeEmerging player
Description

Clinical-stage mental health platform developing psychedelic and non-psychedelic therapies for depression and other neuropsychiatric indications. Competes for the same underserved MDD patient pool with novel mechanisms.

TypeDirect peer
Description

Approved Auvelity (dextromethorphan/bupropion), an NMDA-receptor-targeting therapy for major depressive disorder. Closest mechanistic and indication-level peer to Clexio's CLE-100 program.

TypeDirect peer
Description

Developing XEN1101, a KV7.2/3 channel opener for epilepsy and MDD — directly comparable mechanism to Clexio's CLE-043 asset and a benchmark for that program's clinical pathway.

TypeDirect peer
Description

CNS-focused biopharma commercializing Zurzuvae (zuranolone) for postpartum depression and pursuing other neuropsychiatric indications. Comparable clinical-stage CNS pipeline and commercialization model.

TypeDirect peer
Description

Neurology and psychiatry-focused biopharma with programs in depression and other CNS indications. Similar indication targeting and clinical-stage profile post its spin-out restructuring.

TypeDirect peer
Description

Developed xanomeline-trospium (Cobenfy) for schizophrenia and has CNS pipeline activity. Recent acquisition by BMS illustrates the strategic M&A appetite for differentiated CNS assets.

TypeDirect peer
Description

Clinical-stage CNS biopharma with pipeline across depression, schizophrenia, and epilepsy; acquired by AbbVie for ~$8.7B. Highly comparable neuroscience pipeline orientation.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Clexio Biosciences

Clinical-Stage Neuropsychiatric Pharmaceuticalsclexio.com

Clexio Biosciences is a clinical-stage Israeli pharmaceutical company developing CLE-100 (an oral NMDA receptor antagonist in Phase 2 trials) and CLE-043 (a KV7.2/3 channel opener in preclinical) for patients with treatment-resistant Major Depressive Disorder and Epilepsy.

What Clexio Biosciences does

Clexio Biosciences Ltd. is a clinical-stage pharmaceutical company founded in Israel (Yokne'am headquarters with a secondary office in Petach Tikva) that designs novel small-molecule drugs based on validated mechanisms of action in neuropsychiatry. Its pipeline targets two indications with documented unmet need: Major Depressive Disorder (MDD) and Epilepsy. The lead asset, CLE-100, is an oral NMDA receptor antagonist tablet (esketamine-class mechanism) with high affinity to the PCP site of the NMDA receptor, being developed as an add-on treatment for MDD patients with inadequate response to standard antidepressants; it is currently in Phase 2 multicenter studies in the United States (SOLEO study, initiated April 2024, 50% enrolled by December 2024), following the earlier CLEO Phase 2 proof-of-concept study in 2023. The second asset, CLE-043, is a KV7.2/3 channel opener in preclinical development for Epilepsy and MDD, with a lead compound identified. CLE-100 is protected by three issued US method-of-use patents and three additional allowed US patents, and the program has been supported by patient-advocacy engagement (DBSA) and translational neuroscience partnerships (NeuroKaire).

The company is privately held, pre-revenue, and operates with an 11-50 person organization. Its commercial model will ultimately rely on pharmaceutical drug sales following regulatory approval, with the addressable patient population being adults with treatment-resistant MDD — a segment in which approximately one-third of patients do not achieve remission even after four antidepressant trials, according to the STAR*D data Clexio cites. The team is composed largely of former Teva Pharmaceuticals executives across R&D, clinical, regulatory, legal, and business development functions, complemented by senior leaders with FDA, Roche-Genentech, Merck, and Novo Nordisk backgrounds. The go-to-market is currently clinical-trial-driven: US-based Phase 2 site activation, ClinicalTrials.gov recruitment (NCT06340958), patient advocacy partnerships, and scientific conference presentations (ASCP 2023, CNS Summit 2024, Oxford Conference on Ketamine and Related Compounds). Clexio discloses no commercial customers, no licensing revenue, and no external funding rounds in the available data, making its economics entirely dependent on continued clinical progress and future capital formation.

Clexio Biosciences firmographics

Firmographics
Name
Clexio Biosciences
Legal name
Clexio Biosciences Ltd.
Website
https://clexio.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
11–50 employees
Short description
Clexio Biosciences is a clinical-stage Israeli pharmaceutical company developing CLE-100 (an oral NMDA receptor antagonist in Phase 2 trials) and CLE-043 (a KV7.2/3 channel opener in preclinical) for patients with treatment-resistant Major Depressive Disorder and Epilepsy.
Ownership category
akta.pro rank

Where Clexio Biosciences is headquartered

Location

Headquarters

HQ city
Jerusalem
HQ country
Israel
HQ region
Middle East

Offices2 records

Markets served

Clexio Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Drug Sales: Pre-revenue clinical-stage pharmaceutical company. Revenue will be generated through commercialization of novel drugs following FDA and regulatory approval. The company is developing CLE-100 for Major Depressive Disorder and CLE-043 for Epilepsy and MDD.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Clexio Biosciences product offering

Product offering

Core offering

Clexio Biosciences is a clinical-stage pharmaceutical company designing novel drug candidates based on validated Mechanisms of Action in Neuropsychiatry. Its lead asset CLE-100 is an NMDA receptor antagonist tablet in Phase 2 trials as an add-on therapy for patients with Major Depressive Disorder who have inadequate response to standard antidepressants. Its second asset CLE-043 is a KV7.2/3 channel opener in preclinical development for Epilepsy and MDD.

Product overview

Clexio is a multi-asset clinical-stage pharmaceutical company developing two novel drug candidates based on validated Mechanisms of Action in Neuropsychiatry. The lead product, CLE-100 (an NMDA antagonist tablet), is currently in Phase 2 multicenter studies in the United States for Major Depressive Disorder. The second candidate, CLE-043 (a KV7.2/3 channel opener), is in preclinical development for Epilepsy and MDD. Both products target unmet needs in patients who have not found effective solutions for their neuropsychiatric conditions.

Differentiator

Problem solved

Functional benefit

Products and services

  • CLE-100 CLE-100 is an investigational NMDA receptor antagonist tablet developed as an add-on treatment for patients with Major Depressive Disorder who have inadequate response to standard antidepressant therapy, targeting a more rapid antidepressant effect than most current medications.
  • CLE-043 CLE-043 is a KV7.2/3 channel opener being developed for the treatment of Epilepsy and Major Depressive Disorder; currently in preclinical development with lead compound identified.

Quantifiable outcome

  • Phase 2 CLEO study showed good safety profile and promising efficacy in subgroup of subjects enrolled during post-acute Covid period
  • +1 more outcomes

Companies that use Clexio Biosciences

Customer profile

Segments2 records

Ideal customer profiles2 records

Clexio Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Clexio Biosciences partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor and core.

  • NeuroKaireminorStrategic or Co-development Partner · 1 November 2024Collaboration on profiling drug response mechanisms and patient sub-populations through readouts from a biobank of patient-derived neurons. Collaboration presented at CNS Summit 2024.
  • Depression Bipolar Support Alliance (DBSA)coreStrategic or Co-development Partner · 1 January 2024Clexio partnered with the Depression Bipolar Support Alliance (DBSA) to evaluate the readability of the Informed Consent Form (ICF) designed for their Phase 2 trial in patients with Major Depressive Disorder. The feedback from patients enabled modifications to better explain trial procedures and ensure clear, concise information.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Clexio Biosciences competitors and assessment

Company assessment

Broad incumbents

Emerging players

  • COMPASS Pathways: Developing psilocybin-based therapy for treatment-resistant depression. Competes for the same TRD patient population with a novel mechanism rather than NMDA antagonism.
  • atai Life Sciences: Clinical-stage mental health platform developing psychedelic and non-psychedelic therapies for depression and other neuropsychiatric indications. Competes for the same underserved MDD patient pool with novel mechanisms.

Direct peers

  • Neumora Therapeutics: Clinical-stage neuroscience company developing precision therapeutics for brain diseases including depression. Comparable in stage, indication focus, and pipeline breadth.
  • Axsome Therapeutics: Approved Auvelity (dextromethorphan/bupropion), an NMDA-receptor-targeting therapy for major depressive disorder. Closest mechanistic and indication-level peer to Clexio's CLE-100 program.
  • Xenon Pharmaceuticals: Developing XEN1101, a KV7.2/3 channel opener for epilepsy and MDD — directly comparable mechanism to Clexio's CLE-043 asset and a benchmark for that program's clinical pathway.
  • Sage Therapeutics: CNS-focused biopharma commercializing Zurzuvae (zuranolone) for postpartum depression and pursuing other neuropsychiatric indications. Comparable clinical-stage CNS pipeline and commercialization model.
  • Biohaven Pharmaceutical: Neurology and psychiatry-focused biopharma with programs in depression and other CNS indications. Similar indication targeting and clinical-stage profile post its spin-out restructuring.
  • Karuna Therapeutics (acquired by Bristol Myers Squibb): Developed xanomeline-trospium (Cobenfy) for schizophrenia and has CNS pipeline activity. Recent acquisition by BMS illustrates the strategic M&A appetite for differentiated CNS assets.
  • Cerevel Therapeutics (acquired by AbbVie): Clinical-stage CNS biopharma with pipeline across depression, schizophrenia, and epilepsy; acquired by AbbVie for ~$8.7B. Highly comparable neuroscience pipeline orientation.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Clexio Biosciences social profiles

Digital presence

Clexio Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Clexio Biosciences leadership team

Management profile

Number of profiles

Profiles8 records

Clexio Biosciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Clexio Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Clexio Biosciences

What does Clexio Biosciences do?

Clexio Biosciences is a clinical-stage pharmaceutical company designing novel drug candidates based on validated Mechanisms of Action in Neuropsychiatry. Its lead asset CLE-100 is an NMDA receptor antagonist tablet in Phase 2 trials as an add-on therapy for patients with Major Depressive Disorder who have inadequate response to standard antidepressants. Its second asset CLE-043 is a KV7.2/3 channel opener in preclinical development for Epilepsy and MDD.

Is Clexio Biosciences a public or private company?

Clexio Biosciences is a private company. It is classified as unknown and is currently operating.

When was Clexio Biosciences founded?

Clexio Biosciences was founded in 2009. It employs 11 to 50 people.

Where is Clexio Biosciences based?

Clexio Biosciences is headquartered in Jerusalem, Israel, in the Middle East region.

How does Clexio Biosciences make money?

One revenue line is on record: pharmaceutical Drug Sales.

Who are Clexio Biosciences's main competitors?

Janssen Pharmaceuticals (Johnson & Johnson) is listed as a broad incumbent. Emerging players are COMPASS Pathways and atai Life Sciences. Direct peers are Neumora Therapeutics, Axsome Therapeutics, Xenon Pharmaceuticals, Sage Therapeutics, Biohaven Pharmaceutical, Karuna Therapeutics (acquired by Bristol Myers Squibb) and Cerevel Therapeutics (acquired by AbbVie).

Does Clexio Biosciences have an API?

No public API is recorded for Clexio Biosciences.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals